Classification, Evaluation, and Management of Congenital Peripheral Vascular Malformations

Chapter

Abstract

The International Society for Study of Vascular Anomalies (ISSVA) categorizes congenital vascular malformations by their flow properties into high-flow arteriovenous malformations, slow-flow venous and lymphatic malformations, and congenital mixed syndromes. Despite historically confusing and often conflicting nomenclature and classification schemes, our understanding of the natural history, hemodynamics, and treatment outcomes of these lesions has expanded and evolved over the last few decades. As such, certain fundamental diagnostic and therapeutic principles have been established and are considered standard of care. It is crucial to adhere to these overarching principles in the overall management of these lesions. These are highlighted and expanded upon in this chapter. Furthermore, recently discovered biomolecular pathways implicated in the pathogenesis of vascular malformations and affiliated syndromes are briefly reviewed.

References

  1. 1.
    Nassiri N, Cirillo-Penn NC, Thomas J. Evaluation and management of peripheral arteriovenous malformations. J Vasc Surg. 2015;62(6):1667–76.CrossRefPubMedGoogle Scholar
  2. 2.
    Sundararajan SH, Nassiri N. Regarding “cavernous hemangioma of the external carotid artery”. J Vasc Surg. 2014;60:1412.CrossRefPubMedGoogle Scholar
  3. 3.
    Clemens RK, Pfammatter T, Meier TO, Alomari AI, Amann-Vesti BR. Vascular malformations revisited. Vasa. 2015;44:5–22.CrossRefPubMedGoogle Scholar
  4. 4.
    Nassiri N, Dudiy Y, Carroccio A, Rosen RJ. Transarterial treatment of congenital renal arteriovenous fistulas. J Vasc Surg. 2013;58:1310–5.CrossRefPubMedGoogle Scholar
  5. 5.
    Hassanein AH, Mulliken JB, Fishman SJ, Greene AK. Evaluation of terminology for vascular anomalies in current literature. Plast Reconstr Surg. 2011;127:347–51.CrossRefPubMedGoogle Scholar
  6. 6.
    Nassiri N, Thomas J, Cirillo-Penn NC. Evaluation and management of peripheral venous and lymphatic malformations. J Vasc Surg Venous Lymphat Disord. 2016;4(2):257–65.CrossRefPubMedGoogle Scholar
  7. 7.
    Mulliken JB, Glowacki J. Hemangiomas and vascular malformations in infants and children: a classification based on endothelial characteristics. Plast Reconstr Surg. 1982;69:412–22.CrossRefPubMedGoogle Scholar
  8. 8.
    ISSVA Classification for Vascular Anomalies © International Society for the Study of Vascular Anomalies. 2014. www.issva.org/classification.
  9. 9.
    Brouillard P, Vikkula M. Genetic causes of vascular malformations. Hum Mol Genet. 2007;16:R140–9.CrossRefPubMedGoogle Scholar
  10. 10.
    Luks VL, Kamitaki N, Vivero MP, Uller W, Rab R, Bovee JV, et al. Lymphatic and other vascular malformative/overgrowth disorders are caused by somatic mutations in PIK3CA. J Pediatr. 2015;166:1048–54. e1–5.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Burrows PE. Endovascular treatment of slow-flow vascular malformations. Tech Vasc Interv Radiol. 2013;16:12–21.CrossRefPubMedGoogle Scholar
  12. 12.
    Chaudry G, Burrows PE, Padua HM, Dillon BJ, Fishman SJ, Alomari AI. Sclerotherapy of abdominal lymphatic malformations with doxycycline. J Vasc Interv Radiol. 2011;22:1431–5.CrossRefPubMedGoogle Scholar
  13. 13.
    Garzon MC, Huang JT, Enjolras O, Frieden IJ. Vascular malformations: part I. J Am Acad Dermatol. 2007;56:353–70.CrossRefPubMedGoogle Scholar
  14. 14.
    Gloviczki P, Duncan A, Kalra M, Oderich G, Ricotta J, Bower T, et al. Vascular malformations: an update. Perspect Vasc Surg Endovasc Ther. 2009;21:133–48.CrossRefPubMedGoogle Scholar
  15. 15.
    Mohan AT, Adams S, Adams K, Hudson DA. Intralesional bleomycin injection in management of low flow vascular malformations in children. J Plast Surg Hand Surg. 2014;49:1–5.Google Scholar
  16. 16.
    Dompmartin A, Vikkula M, Boon LM. Venous malformation: update on etiopathogenesis, diagnosis and management. Phlebology. 2010;25:224–35.CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    Paltiel HJ, Burrows PE, Kozakewich HP, Zurakowski D, Mulliken JB. Soft-tissue vascular anomalies: utility of US for diagnosis. Radiology. 2000;214:747–54.CrossRefPubMedGoogle Scholar
  18. 18.
    Nosher JL, Murillo PG, Liszewski M, Gendel V, Gribbin CE. Vascular anomalies: a pictorial review of nomenclature, diagnosis and treatment. World J Radiol. 2014;6:677–92.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lee BB, Do YS, Byun HS, Choo IW, Kim DI, Huh SH. Advanced management of venous malformation with ethanol sclerotherapy: mid- term results. J Vasc Surg. 2003;37:533–8.CrossRefPubMedGoogle Scholar
  20. 20.
    Gloviczki P, Driscoll DJ. Klippel-Trenaunay syndrome: current management. Phlebology. 2007;22:291–8.CrossRefPubMedGoogle Scholar
  21. 21.
    Steiner F, FitzJohn T, Tan ST. Ethanol sclerotherapy for venous malformation. ANZ J Surg. 2016;86(10):790–5.CrossRefPubMedGoogle Scholar
  22. 22.
    Wong GA, Armstrong DC, Robertson JM. Cardiovascular collapse during ethanol sclerotherapy in a pediatric patient. Paediatr Anaesth. 2006;16:343–6.CrossRefPubMedGoogle Scholar
  23. 23.
    Yakes WF, Luethke JM, Merland JJ, Rak KM, Slater DD, Hollis HW, et al. Ethanol embolization of arteriovenous fistulas: a primary mode of therapy. J Vasc Interv Radiol. 1990;1:89–96.CrossRefPubMedGoogle Scholar
  24. 24.
    Yakes WF, Luethke JM, Parker SH, Stavros AT, Rak KM, Hopper KD, et al. Ethanol embolization of vascular malformations. Radiographics. 1990;10:787–96.CrossRefPubMedGoogle Scholar
  25. 25.
    Lee BB, Kim DI, Huh S, Kim HH, Choo IW, Byun HS, et al. New experiences with absolute ethanol sclerotherapy in the management of a complex form of congenital venous malformation. J Vasc Surg. 2001;33:764–72.CrossRefPubMedGoogle Scholar
  26. 26.
    Kok K, McCafferty I, Monaghan A, Nishikawa H. Percutaneous sclerotherapy of vascular malformations in children using sodium tet- radecyl sulphate: the Birmingham experience. J Plast Reconstr Aesthet Surg. 2012;65:1451–60.CrossRefPubMedGoogle Scholar
  27. 27.
    Burrows PE, Mitri RK, Alomari A, Padua HM, Lord DJ, Sylvia MB, et al. Percutaneous sclerotherapy of lymphatic malformations with doxycycline. Lymphat Res Biol. 2008;6:209–16.CrossRefPubMedGoogle Scholar
  28. 28.
    Levitin GM, Thompson SH, Berenstein A, Waner M. Surgical treat- ment of buccofacial region vascular anomalies using an intraoral buccomucosal flap procedure. Arch Otolaryngol Head Neck Surg. 2010;136:134–7.CrossRefPubMedGoogle Scholar
  29. 29.
    Jiang Z, Li S, Kretlow JD, Cao W. Closure of large defects after microcystic lymphatic malformations using lateral intercostal artery perforator flap. J Plast Reconstr Aesthet Surg. 2014;67:1230–6.CrossRefPubMedGoogle Scholar
  30. 30.
    Niti K, Manish P. Microcystic lymphatic malformation (lymphangioma circumscriptum) treated using a minimally invasive technique of radiofrequency ablation and sclerotherapy. Dermatol Surg. 2010;36:1711–7.CrossRefPubMedGoogle Scholar
  31. 31.
    Raveh E, Waner M, Kornreich L, Segal K, Ben-Amitai D, Kalish E, et al. The current approach to hemangiomas and vascular malformations of the head and neck [in Hebrew]. Harefuah. 2002;141:783–8, 859, 858PubMedGoogle Scholar
  32. 32.
    Nassiri N, TM O, Rosen RJ, Moritz J, Waner M. Staged endovascular and surgical treatment of slow-flow vulvar venous malformations. Am J Obstet Gynecol. 2013;208:366.e1–6.CrossRefGoogle Scholar
  33. 33.
    Lee BB, Baumgartner I, Berlien HP, Bianchini G, Burrows P, Do YS, et al. Consensus document of the International Union of Angiology (IUA)-2013. Current concept on the management of arteriovenous management. Int Angiol. 2013;32:9–36.PubMedGoogle Scholar
  34. 34.
    Blei F. Medical and genetic aspects of vascular anomalies. Tech Vasc Interv Radiol. 2013;16:2–11.CrossRefPubMedGoogle Scholar
  35. 35.
    Alomari A, Dubois J. Interventional management of vascular malformations. Tech Vasc Interv Radiol. 2011;14:22–31.CrossRefPubMedGoogle Scholar
  36. 36.
    Blei F, Bittman M. Congenital vascular anomalies: current perspectives on diagnosis, classification, and management. J Vasc Diagn Interv. 2016;4:23–37.Google Scholar
  37. 37.
    Limaye N, Wouters V, Uebelhoer M, Tuominen M, Wirkkala R, Mulliken JB, et al. Somatic mutations in angiopoietin receptor gene TEK cause solitary and multiple sporadic venous malformations. Nat Genet. 2009;41:118–24.CrossRefPubMedGoogle Scholar
  38. 38.
    Burrows PE. Vascular malformations involving the female pelvis. Semin Interv Radiol. 2008;25:347–60.CrossRefGoogle Scholar
  39. 39.
    Frasier K, Giangola G, Rosen R, Ginat DT. Endovascular radio-frequency ablation: a novel treatment of venous insufficiency in Klippel-Trenaunay patients. J Vasc Surg. 2008;47:1339–45.CrossRefPubMedGoogle Scholar
  40. 40.
    Rosenblatt M. Endovascular management of venous malformations. Phlebology. 2007;22:264–75.CrossRefPubMedGoogle Scholar
  41. 41.
    Nishida T, Faughnan ME, Krings T, Chakinala M, Gossage JR, Young WL, et al. Brain arteriovenous malformations associated with hereditary hemorrhagic telangiectasia: gene-phenotype correlations. Am J Med Genet A. 2012;158A:2829–34.CrossRefPubMedGoogle Scholar
  42. 42.
    Rosen RJ, Nassiri N, Drury JE. Interventional management of high- flow vascular malformations. Tech Vasc Interv Radiol. 2013;16:22–38.CrossRefPubMedGoogle Scholar
  43. 43.
    Rosen RJ, Nassiri N. Visceral and extremity arteriovenous malformation. In: Kandarpa K, Machan L, editors. Handbook of interventional radiologic procedures. 4th ed. Philadelphia: Lippincott/Williams/Wilkins; 2010. p. 287–96.Google Scholar
  44. 44.
    Murphy PA, Kim TN, Lu G, Bollen AW, Schaffer CB, Wang RA. Notch4 normalization reduces blood vessel size in arteriovenous malformations. Sci Transl Med. 2012;4:117ra8.CrossRefPubMedPubMedCentralGoogle Scholar
  45. 45.
    Tu J, Li Y, Hu Z. Notch1 and 4 signaling responds to an increasing vascular wall shear stress in a rat model of arteriovenous malformations. Biomed Res Int. 2014;2014:368082.PubMedPubMedCentralGoogle Scholar
  46. 46.
    Tu J, Li Y, Hu Z, Chen Z. Radiosurgery inhibition of the Notch signaling pathway in a rat model of arteriovenous malformations. J Neurosurg. 2014;120:1385–96.CrossRefPubMedGoogle Scholar
  47. 47.
    Rutherford RB. Noninvasive evaluation for congenital arteriovenous fistulas and malformations. Semin Vasc Surg. 2012;25:49–57.CrossRefPubMedGoogle Scholar
  48. 48.
    Yakes WF. Endovascular management of high-flow arteriovenous malformations. Semin Interv Radiol. 2004;21:49–58.CrossRefGoogle Scholar
  49. 49.
    Trerotola SO, Pyeritz RE. PAVM embolization: an update. Am J Roentgenol. 2010;195:837–45.CrossRefGoogle Scholar
  50. 50.
    Yakes WF. Yakes’ AVM classification system. J Vasc Interv Radiol. 2015;26:S224.CrossRefGoogle Scholar
  51. 51.
    Rosen RJ, Drury J. Interventional management of vascular malformations. In: Kipshidze N, Fareed J, Rosen RJ, Dangas G, Surreys PW, editors. Urgent interventional therapies. Hoboken: Wiley; 2014. p. 419–41.Google Scholar
  52. 52.
    Pollak J, White RJ. Embolization for pulmonary vascular malformations. In: Kandarpa K, Machan L, editors. Handbook of interventional radiologic procedures. 4th ed. Philadelphia: Lippincott, Williams, & Wilkins; 2010.Google Scholar
  53. 53.
    Pollak JS, White RJ. Distal cross-sectional occlusion is the “key” to treating pulmonary arteriovenous malformations. J Vasc Interv Radiol. 2012;23:1578–80.CrossRefPubMedGoogle Scholar
  54. 54.
    Nassiri N, Rosen RJ. Pulmonary arteriovenous malformations. In: Urgent interventional therapies. New York: Wiley; 2014. p. 410–8.Google Scholar
  55. 55.
    Nassiri N, Thomas J, Rahimi S. Fibrodysplastic implications for transvenous embolization of a high-flow pelvic arteriovenous malformation in Osler-Weber-Rendu syndrome. J Vasc Surg Cases. 2015;1:16–9.CrossRefGoogle Scholar
  56. 56.
    Marrone G, Caruso S, Miraglia R, Tarantino I, Volpes R, Luca A. Percutaneous transarterial embolization of extrahepatic arteroportal fistula. World J Gastroenterol. 2006;12:5562–4.CrossRefPubMedPubMedCentralGoogle Scholar
  57. 57.
    Lee BB, Do YS, Yakes W, Kim DI, Mattassi R, Hyon WS. Management of arteriovenous malformations: a multidisciplinary approach. J Vasc Surg. 2004;39:590–600.CrossRefPubMedGoogle Scholar
  58. 58.
    Park UJ, Do YS, Park KB, Park HS, Kim YW, Lee BB, et al. Treatment of arteriovenous malformations involving the hand. Ann Vasc Surg. 2012;26:643–8.CrossRefPubMedGoogle Scholar
  59. 59.
    White RI, Pollak JS, Wirth JA. Pulmonary arteriovenous malformations: diagnosis and transcatheter embolotherapy. J Vasc Interv Radiol. 1996;7:787–804.CrossRefPubMedGoogle Scholar
  60. 60.
    Yakes WF, Haas DK, Parker SH, Gibson MD, Hopper KD, Mulligan JS, et al. Symptomatic vascular malformations: ethanol embolotherapy. Radiology. 1989;170:1059–66.CrossRefPubMedGoogle Scholar
  61. 61.
    White RI, Pollak J, Persing J, Henderson KJ, Thomson JG, Burdge CM. Long-term outcome of embolotherapy and surgery for high-flow extremity arteriovenous malformations. J Vasc Interv Radiol. 2000;11:1285–95.CrossRefPubMedGoogle Scholar
  62. 62.
    Park HS, Do YS, Park KB, Kim DI, Kim YW, Kim MJ, et al. Ethanol embolotherapy of hand arteriovenous malformations. J Vasc Surg. 2011;53:725–31.CrossRefPubMedGoogle Scholar
  63. 63.
    Coldwell DM, Stokes KR, Yakes WF. Embolotherapy: agents, clinical applications, and techniques. Radiogr Rev Publ Radiol Soc N Am. 1994;14:623–43.Google Scholar
  64. 64.
    Rammos S, Bortolotti C, Lanzino G. Endovascular management of intracranial dural arteriovenous fistulae. Neurosurg Clin N Am. 2014;25:539–49.CrossRefPubMedGoogle Scholar
  65. 65.
    Consoli A, Renieri L, Nappini S, Limbucci N, Mangiafico S. Endovascular treatment of deep hemorrhagic brain arteriovenous malformations with transvenous onyx embolization. AJNR Am J Neuroradiol. 2013;34:1805–11.CrossRefPubMedGoogle Scholar
  66. 66.
    McCaffery TD, Lilly JO. Hereditary telangiectasia manifested as gastrointestinal bleeding without external visible telangiectasia. Am J Gastroenterol. 1975;63:327–32.PubMedGoogle Scholar
  67. 67.
    Sofocleous CT, Rosen RJ, Raskin K, Fioole B, Hofstee DJ. Congenital vascular malformations in the hand and forearm. J Endovasc Ther. 2001;8:484–94.CrossRefPubMedGoogle Scholar
  68. 68.
    Do YS, Park KB, Park HS, Cho SK, Shin SW, Moon JW, et al. Extremity arteriovenous malformations involving the bone: therapeutic outcomes of ethanol embolotherapy. J Vasc Interv Radiol. 2010;21:807–16.CrossRefPubMedGoogle Scholar
  69. 69.
    Hyun D, Do YS, Park KB, Kim DI, Kim YW, Park HS, et al. Ethanol embolotherapy of foot arteriovenous malformations. J Vasc Surg. 2013;58:1619–26.CrossRefPubMedGoogle Scholar
  70. 70.
    Hill RA, Pho RW, Kumar VP. Resection of vascular malformations. J Hand Surg Edinb Scotl. 1993;18:17–21.CrossRefGoogle Scholar
  71. 71.
    Yakes WF, Krauth L, Ecklund J, Swengle R, Dreisbach JN, Seibert CE, et al. Ethanol endovascular management of brain arteriovenous malformations: initial results. Neurosurgery. 1997;40:1145–52. discussion: 1152–4.CrossRefPubMedGoogle Scholar
  72. 72.
    Yakes WF, Pevsner P, Reed M, Donohue HJ, Ghaed N. Serial embolizations of an extremity arteriovenous malformation with alcohol via direct percutaneous puncture. AJR Am J Roentgenol. 1986;146:1038–40.CrossRefPubMedGoogle Scholar
  73. 73.
    Tan KT, Simons ME, Rajan DK, Terbrugge K. Peripheral high-flow arteriovenous vascular malformations: a single-center experience. J Vasc Interv Radiol. 2004;15:1071–80.CrossRefPubMedGoogle Scholar
  74. 74.
    Rockman CB, Rosen RJ, Jacobowitz GR, Weiswasser J, Hofstee DJ, Fioole B, et al. Transcatheter embolization of extremity vascular malformations: the long-term success of multiple interventions. Ann Vasc Surg. 2003;17:417–23.CrossRefPubMedGoogle Scholar
  75. 75.
    Lee BB, Baumgartner I, Berlien P, Bianchini G, Burrows P, Gloviczki P, et al. Diagnosis and treatment of venous malformations. Consensus document of the International Union of Phlebology (IUP): updated 2013. Int Angiol. 2015;34:97–149.PubMedGoogle Scholar
  76. 76.
    Jeong HS, Baek CH, Son YI, Kim TW, Lee BB, Byun HS. Treatment for extracranial arteriovenous malformations of the head and neck. Acta Otolaryngol (Stockh). 2006;126:295–300.CrossRefGoogle Scholar
  77. 77.
    Wang D, Su L, Fan X. Cardiovascular collapse and disseminated intravascular coagulation as complications of ethanol embolization of arteriovenous malformations in the upper lip: case report and literature review. J Oral Maxillofac Surg. 2014;72:346–51.CrossRefPubMedGoogle Scholar
  78. 78.
    Cho CH, Choi JS. Permanent ulnar nerve palsy after embolotherapy of arteriovenous malformation around the elbow. Hand Surg. 2011;16:167–9.CrossRefPubMedGoogle Scholar
  79. 79.
    Salloum R, Fox CE, Alvarez-Allende CR, Hammill AM, Dasgupta R, Dickie BH, et al. Response of blue rubber bleb nevus syndrome to sirolimus treatment. Pediatr Blood Cancer. 2016;63(11):1911–4.CrossRefPubMedGoogle Scholar
  80. 80.
    Yesil S, Tanyildiz HG, Bozkurt C, Cakmakci E, Sahin G. Single-center experience with sirolimus therapy for vascular malformations. Pediatr Hematol Oncol. 2016;33(3):219–25.CrossRefPubMedGoogle Scholar
  81. 81.
    Boscolo E, Limaye N, Huang L, Kang K, Soblet J, Uebelhoer M, et al. Rapamycin improves TIE2-mutated venous malformation in murine model and human subjects. J Clin Invest. 2015;125(9):3491–504.CrossRefPubMedPubMedCentralGoogle Scholar
  82. 82.
    Trujillo G, Lapunzina P, del Pozo A, Rodriguez L, Ibanez K, Tenorio J, et al. PIK3CA mutations in vascular malformations. Presented at International Society for the Study of Vascular Anomalies (ISSVA) 21st International Workshop on Vascular Anomalies; April 26–29; Buenos Aires, Argentina; 2016. Abstract 155.Google Scholar
  83. 83.
    Soblet J, Kangas J, Natynki M, Mendola A, Helaers R, Uebelhoer M, et al. Blue rubber bleb nevus (BRBN) syndrome is caused by somatic TEK (TIE2) mutations. J Invest Dermatol. 2016;137(1):207–16.CrossRefPubMedGoogle Scholar
  84. 84.
    Jin XL, Wang ZH, Xiao XB, Huang LS, Zhao XY. Blue rubber bleb nevus syndrome: a case report and literature review. World J Gastroenterol. 2014;20:17254–9.CrossRefPubMedPubMedCentralGoogle Scholar
  85. 85.
    Ivars M, Redondo P. Efficacy of topical sirolimus (Rapamycin) for the treatment of microcystic lymphatic malformations. JAMA Dermatol. 2016.  https://doi.org/10.1001/jamadermatol.2016.3697. [epub ahead of print].
  86. 86.
    Boon L, Hammer J, Duez S, Seront E, Van Damme A, Hoyoux C, et al. Rapamycin as novel treatment for refractory to standard care lymphatic anomalies. Presented at International Society for the Study of Vascular Anomalies (ISSVA) 21st International Workshop on Vascular Anomalies; April 26–29; Buenos Aires, Argentina; 2016. Abstract 220.Google Scholar
  87. 87.
    Grunewald TG, Damke L, Maschan M, et al. First report of effective and feasible treatment of multifocal lymphangiomatosis (Gorham-Stout) with bevacizumab in a child. Ann Oncol. 2010;21(8):1733–4.CrossRefPubMedGoogle Scholar
  88. 88.
    Swetman GL, Berk DR, Vasanawala SS, Feinstein JA, Lane AT, Bruckner AL. Sildenafil for severe lymphatic malformations. N Engl J Med. 2012;366(4):384–6.CrossRefPubMedGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Vascular and Endovascular SurgeryYale School of Medicine, Yale New Haven Hospital, VA Connecticut Healthcare SystemsNew HavenUSA
  2. 2.Rutgers Robert Wood Johnson Medical SchoolNew BrunswickUSA

Personalised recommendations